First Results From a Randomized Phase 2 Study of Cabazitaxel vs an Androgen Receptor-Targeted Agent in Patients With Poor-Prognosis Castration-Resistant Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [41] Nomogram Analysis for Predicting Response to Androgen-Receptor-Axis-Targeted Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer
    Shao, I-Hung
    Wang, Hsiang-Shen
    Hsieh, Chin-Hsuan
    Lee, Tsung-Lin
    Chang, Ying-Hsu
    Huang, Liang-Kang
    Chu, Yuan-Cheng
    Kan, Hung-Chen
    Lin, Po-Hung
    Yu, Kai-Jie
    Wu, Chun-Te
    Chuang, Cheng-Keng
    Pang, See-Tong
    CANCER MEDICINE, 2024, 13 (21):
  • [42] Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan
    Matsubara, Nobuaki
    Suzuki, Kazuhiro
    Kazama, Hirotaka
    Tsukube, Shoko
    Seto, Takeshi
    Matsuyama, Hideyasu
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (07) : 1067 - 1073
  • [43] Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Hirofumi Mukai
    Shunji Takahashi
    Masahiro Nozawa
    Yusuke Onozawa
    Jun Miyazaki
    Keiji Ohno
    Kazuhiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 703 - 710
  • [44] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tomohiro Tsuchiya
    Keiichiro Imanaka
    Yuki Iwaki
    Ryo Oyama
    Katsuyoshi Hashine
    Akito Yamaguchi
    Hiroji Uemura
    International Journal of Clinical Oncology, 2019, 24 : 1596 - 1604
  • [45] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tsuchiya, Tomohiro
    Imanaka, Keiichiro
    Iwaki, Yuki
    Oyama, Ryo
    Hashine, Katsuyoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (12) : 1596 - 1604
  • [46] Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tripathi, N.
    Chigarira, B.
    Sayegh, N.
    Thomas, V. Mathew
    Kumar, S. Adidam
    Goel, D.
    Tandar, C.
    Mcfarland, T. R.
    Nussenzveig, R.
    Sirohi, D.
    Swami, U.
    Maughan, B. L.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1184 - S1184
  • [47] A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer
    Aggarwal, Rahul Raj
    Weinberg, Vivian K.
    Ryan, Charles J.
    Harzstark, Andrea Lynne
    Bryce, Alan Haruo
    Derleth, Christina Louise
    Lowe, Kimberly
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
    Winquist, Eric
    Hotte, Sebastien J.
    Chi, Kim
    Sridhar, Srikala
    Ellard, Susan
    Ong, Michael
    Iqbal, Nayyer
    Salim, Muhammad
    Emmenegger, Urban
    Gingerich, Joel R.
    Lalani, Aly-Khan
    Major, Pierre
    Kollmannsberger, Christian
    Yip, Steven
    Hansen, Aaron
    Finch, Daygen
    Canil, Christina
    Hutchenreuther, James
    Vera-Badillo, Francisco
    Smoragiewicz, Martin
    Cabanero, Michael
    Tsao, Ming-Sound
    Ritch, Elie
    Wyatt, Alexander W.
    Seymour, Lesley
    CLINICAL CANCER RESEARCH, 2025, 31 (01) : 45 - 55
  • [49] Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Mukai, Hirofumi
    Takahashi, Shunji
    Nozawa, Masahiro
    Onozawa, Yusuke
    Miyazaki, Jun
    Ohno, Keiji
    Suzuki, Kazuhiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 703 - 710
  • [50] Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
    Sternberg, Cora N.
    De Bono, Johann Sebastian
    Chi, Kim N.
    Fizazi, Karim
    Mulders, Peter
    Hirmand, Mohammad
    Forer, David
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345